DrugRepV|Encyclopedia for antivirals

Chemical, Structural, Clinical and Biological details of Antiviral agents ID: DrugRepV_7625

Chemical Information
Antiviral agent ID DrugRepV_7625
Antiviral agent name Lopinavir
IUPAC Name (2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
SMILES (canonical) CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
SMILES (isomeric) CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
Molecular Formula C37H48N4O5
Molecular Weight (g/mol) 628.814

InChl InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1

Common Name ABT-378

Synonyms Aluviran | Kaletra | LPV | Koletra
Structural Information

Clinical Information
Category Antiinfectives For Systemic Use
Primary Indication (Clinical trial phases) Approved
Biological Information
Primary Indication (Disease Category) Infectious Disease
Primary Indication (Disease) Acquired immunodeficiency syndrome
Secondary Indication SARS Coronavirus-2 (SARS-CoV-2) 2 ?CoV/KOR/KCDC03/2020
Secondary Indication (Approaches) Experimental
Secondary Indication (Methods) In-vitro
Secondary Indication (Model system) [cell lines/ animal models] Vero E6 cells (ATCC CCL-81)
Secondary Indication (Mode of viral infection) Adsorption
Secondary Indication (Viral titer) 0.0125 MOI
Secondary Indication (Mode of drug delivery) Culture
Secondary Indication (Drug concentration) 5730.7 ng/mL
Secondary Indication (Cell based assay) Immunofluorescence
Secondary Indication (Change) Decrease
Secondary Indication (Type of Inhibition) EC50 [ 50 % ]
Reference Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A..Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics..Clin Pharmacol Ther. 2020 May 21:10.1002/cpt.1909. doi: 10.1002/cpt.1909. PMCID: PMC7280633. PMID:32438446
Comment Hydroxycloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavirboosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50. Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 1.5-fold in lung, respectively.

Copyright © 2019. CSIR-Institute of Microbial Technology, Chandigarh, INDIA.

Chemical Information
Antiviral agent ID	DrugRepV_7625
Antiviral agent name	Lopinavir
IUPAC Name	(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
SMILES (canonical)	CC1=C(C(=CC=C1)C)OCC(=O)NC(CC2=CC=CC=C2)C(CC(CC3=CC=CC=C3)NC(=O)C(C(C)C)N4CCCNC4=O)O
SMILES (isomeric)	CC1=C(C(=CC=C1)C)OCC(=O)N[C@@H](CC2=CC=CC=C2)[C@H](C[C@H](CC3=CC=CC=C3)NC(=O)[C@H](C(C)C)N4CCCNC4=O)O
Molecular Formula	C37H48N4O5
Molecular Weight (g/mol)	628.814
InChl	InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1
Common Name	ABT-378
Synonyms	Aluviran \| Kaletra \| LPV \| Koletra
Structural Information

Clinical Information
Category	Antiinfectives For Systemic Use
Primary Indication (Clinical trial phases)	Approved
Biological Information
Primary Indication (Disease Category)	Infectious Disease
Primary Indication (Disease)	Acquired immunodeficiency syndrome
Secondary Indication	SARS Coronavirus-2 (SARS-CoV-2) 2 ?CoV/KOR/KCDC03/2020
Secondary Indication (Approaches)	Experimental
Secondary Indication (Methods)	In-vitro
Secondary Indication (Model system) [cell lines/ animal models]	Vero E6 cells (ATCC CCL-81)
Secondary Indication (Mode of viral infection)	Adsorption
Secondary Indication (Viral titer)	0.0125 MOI
Secondary Indication (Mode of drug delivery)	Culture
Secondary Indication (Drug concentration)	5730.7 ng/mL
Secondary Indication (Cell based assay)	Immunofluorescence
Secondary Indication (Change)	Decrease
Secondary Indication (Type of Inhibition)	EC50 [ 50 % ]
Reference	Arshad U, Pertinez H, Box H, Tatham L, Rajoli RKR, Curley P, Neary M, Sharp J, Liptrott NJ, Valentijn A, David C, Rannard SP, O'Neill PM, Aljayyoussi G, Pennington SH, Ward SA, Hill A, Back DJ, Khoo SH, Bray PG, Biagini GA, Owen A..Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics..Clin Pharmacol Ther. 2020 May 21:10.1002/cpt.1909. doi: 10.1002/cpt.1909. PMCID: PMC7280633. PMID:32438446
Comment	Hydroxycloroquine, chloroquine, mefloquine, atazanavir (ritonavir-boosted), tipranavir (ritonavirboosted), ivermectin, azithromycin and lopinavir (ritonavir-boosted) were all predicted to achieve lung concentrations over 10-fold higher than their reported EC50. Nitazoxanide and sulfadoxine also exceeded their reported EC50 by 7.8- and 1.5-fold in lung, respectively.